2026 · 1st Quarter (Jan 1 - Mar 31)
Filed by ARTEMIS POLICY GROUP LLC.
Open official filingSource-reported fields
Literal source text
Issues related to reimbursement for hemophilia services and treatments in Medicare Issues related to reimbursement for hemophilia services and treatments in Medicaid Implementation of H.R. 1, One Big Beautiful Bill Act
Literal federal measure citations: H.R. 1
Implementation of H.R. 1, One Big Beautiful Bill Act Affordable Care Act implementation Coverage of hemophilia treatments and services in private insurance plans Policies related to co-pay accumulators, including the HELP Copays Act (S 864, HR 6423) Private insurance policies that discriminate coverage for high-cost drugs and use of patient assistance programs, also known as Alternative Funding Programs Policies related to the extension of enhanced advanced premium tax credits, including HR 247, HR 1, HR 5371, S 46, HR 1834
Literal federal measure citations: H.R. 1, S 864, HR 6423, HR 247, HR 1, HR 5371, S 46, HR 1834
Issues related to participation in the 340B Drug Discount Program Polices related to PBMs and drug cost transparency
Funding for federal hemophilia programs at CDC and HRSA for FY26 Funding for federal hemophilia programs at CDC and HRSA for FY27
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
